Ilmarinen Mutual Pension Insurance Co Raises Position in Gilead Sciences, Inc. $GILD

Key Points

• Ilmarinen Mutual Pension Insurance Co increased its stake in Gilead Sciences by 12.1% during the first quarter, owning 195,000 shares worth approximately $21.85 million.
• Insider sell-offs include Johanna Mercier, who sold 28,000 shares at an average price of $118.53, resulting in a 19.7% decrease in her holdings in the company.
• Gilead Sciences recently announced a quarterly dividend of $0.79, with a dividend yield of 2.7%, expected to be paid on September 29th to investors of record as of September 15th.

Ilmarinen Mutual Pension Insurance Co raised its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 12.1% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 195,000 shares of the biopharmaceutical company's stock after acquiring an additional 21,000 shares during the period. Ilmarinen Mutual Pension Insurance Co's holdings in Gilead Sciences were worth $21,850,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in GILD. Smallwood Wealth Investment Management LLC purchased a new stake in Gilead Sciences during the 1st quarter worth $25,000. Activest Wealth Management lifted its position in shares of Gilead Sciences by 2,837.5% during the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 227 shares during the last quarter. Goodman Advisory Group LLC bought a new position in shares of Gilead Sciences during the first quarter worth about $29,000. Colonial Trust Advisors lifted its position in shares of Gilead Sciences by 304.3% during the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company's stock worth $32,000 after purchasing an additional 213 shares during the last quarter. Finally, Core Alternative Capital raised its stake in Gilead Sciences by 370.8% during the first quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock worth $34,000 after acquiring an additional 241 shares during the period. Institutional investors and hedge funds own 83.67% of the company's stock.

Insider Buying and Selling at Gilead Sciences

In other news, insider Johanna Mercier sold 28,000 shares of the stock in a transaction on Friday, August 15th. The shares were sold at an average price of $118.53, for a total value of $3,318,840.00. Following the completion of the transaction, the insider owned 114,168 shares in the company, valued at approximately $13,532,333.04. This represents a 19.70% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction on Monday, July 14th. The shares were sold at an average price of $109.74, for a total transaction of $548,700.00. Following the completion of the transaction, the director owned 8,920 shares of the company's stock, valued at approximately $978,880.80. This represents a 35.92% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 82,000 shares of company stock worth $9,371,330. Corporate insiders own 0.27% of the company's stock.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $115.76 on Wednesday. Gilead Sciences, Inc. has a 1 year low of $78.73 and a 1 year high of $121.83. The firm's fifty day simple moving average is $113.77 and its 200 day simple moving average is $109.99. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The firm has a market capitalization of $143.64 billion, a PE ratio of 23.06, a PEG ratio of 0.79 and a beta of 0.36.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.96 by $0.05. The business had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. Gilead Sciences's revenue was up 1.4% compared to the same quarter last year. During the same period last year, the business posted $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be paid a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 2.7%. The ex-dividend date is Monday, September 15th. Gilead Sciences's dividend payout ratio (DPR) is presently 62.95%.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Needham & Company LLC upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 target price for the company in a research report on Friday, July 25th. Daiwa America raised shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, August 19th. Dbs Bank upgraded shares of Gilead Sciences to a "moderate buy" rating in a report on Friday, September 5th. UBS Group boosted their price target on shares of Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a report on Friday, August 8th. Finally, Royal Bank Of Canada raised their target price on Gilead Sciences from $96.00 to $98.00 and gave the stock a "sector perform" rating in a research report on Friday, August 8th. Three research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, Gilead Sciences presently has an average rating of "Moderate Buy" and a consensus price target of $115.39.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.